Sage Therapeutics Statistics
Share Statistics
Sage Therapeutics has 61.17M shares outstanding. The number of shares has increased by 1.77% in one year.
| Shares Outstanding | 61.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.2% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 53.88M |
| Failed to Deliver (FTD) Shares | 2.06K |
| FTD / Avg. Volume | 0.16% |
Short Selling Information
The latest short interest is 6.41M, so 10.48% of the outstanding shares have been sold short.
| Short Interest | 6.41M |
| Short % of Shares Out | 10.48% |
| Short % of Float | 11.9% |
| Short Ratio (days to cover) | 6.74 |
Valuation Ratios
The PE ratio is -2.39 and the forward PE ratio is -1.37.
| PE Ratio | -2.39 |
| Forward PE | -1.37 |
| PS Ratio | 15 |
| Forward PS | 2.9 |
| PB Ratio | 1.62 |
| P/FCF Ratio | -2.4 |
| PEG Ratio | n/a |
Enterprise Valuation
Sage Therapeutics Inc. has an Enterprise Value (EV) of 1.23B.
| EV / Earnings | -2.27 |
| EV / Sales | 14.24 |
| EV / EBITDA | -2.26 |
| EV / EBIT | -2.12 |
| EV / FCF | -2.27 |
Financial Position
The company has a current ratio of 10.51, with a Debt / Equity ratio of 0.
| Current Ratio | 10.51 |
| Quick Ratio | 10.49 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.68% and return on capital (ROIC) is -72.06%.
| Return on Equity (ROE) | -0.68% |
| Return on Assets (ROA) | -0.61% |
| Return on Capital (ROIC) | -72.06% |
| Revenue Per Employee | 177.53K |
| Profits Per Employee | -1.11M |
| Employee Count | 487 |
| Asset Turnover | 0.1 |
| Inventory Turnover | 1.44 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -71.74% in the last 52 weeks. The beta is 0.92, so Sage Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.92 |
| 52-Week Price Change | -71.74% |
| 50-Day Moving Average | 5.67 |
| 200-Day Moving Average | 9.27 |
| Relative Strength Index (RSI) | 69.28 |
| Average Volume (20 Days) | 1.25M |
Income Statement
In the last 12 months, Sage Therapeutics had revenue of 86.45M and earned -541.49M in profits. Earnings per share was -9.05.
| Revenue | 86.45M |
| Gross Profit | 84.30M |
| Operating Income | -579.85M |
| Net Income | -541.49M |
| EBITDA | -545.07M |
| EBIT | -579.85M |
| Earnings Per Share (EPS) | -9.05 |
Balance Sheet
The company has 70.99M in cash and 5.17M in debt, giving a net cash position of 65.83M.
| Cash & Cash Equivalents | 70.99M |
| Total Debt | 5.17M |
| Net Cash | 65.83M |
| Retained Earnings | -2.57B |
| Total Assets | 622.43M |
| Working Capital | 544.58M |
Cash Flow
In the last 12 months, operating cash flow was -540.59M and capital expenditures -553.00K, giving a free cash flow of -541.14M.
| Operating Cash Flow | -540.59M |
| Capital Expenditures | -553.00K |
| Free Cash Flow | -541.14M |
| FCF Per Share | -9.04 |
Margins
Gross margin is 97.5%, with operating and profit margins of -670.69% and -626.32%.
| Gross Margin | 97.5% |
| Operating Margin | -670.69% |
| Pretax Margin | -626.32% |
| Profit Margin | -626.32% |
| EBITDA Margin | -630.47% |
| EBIT Margin | -670.69% |
| FCF Margin | -625.92% |
Dividends & Yields
SAGE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -121.31% |
| FCF Yield | -118.66% |
Analyst Forecast
The average price target for SAGE is $9, which is 20.6% higher than the current price. The consensus rating is "Hold".
| Price Target | $9 |
| Price Target Difference | 20.6% |
| Analyst Consensus | Hold |
| Analyst Count | 19 |
Scores
| Altman Z-Score | -4.03 |
| Piotroski F-Score | 3 |